Evidence Hub

Mycoplasma pneumoniae Pneumonia: Variety of Presentation in Children Case Series

Noor Diana Ashaari Muhamad, Shazreen@Fatihah Shaari, N. K. Nik Yusoff

Malaysian Journal of Paediatrics and Child Health, 2025

Abstract

Mycoplasma pneumoniae (MP) pneumonia remains a significant concern in paediatrics, commonly presenting with prolonged fever, cough, lethargy, and respiratory distress. A recent global resurgence of MP pneumonia post Covid-19 pandemic with macrolide resistant MP posed a major treatment challenge. In this case series, five out of six patients required oxygen, while two developed necrotizing pneumonia and one had bronchiolitis obliterans as a sequelae of MP pneumonia. Recent rise in severe and refractory MP pneumonia highlights the need for improved diagnostic and resistance testing, particularly through rapid polymerase chain reaction (PCR) methods. Timely identification and intervention of severe infection is important to avoid sequelae. Management should include appropriate antibiotics, supportive care, and corticosteroids when indicated. Severe cases may require early referral to a paediatric intensive care unit, as well as input from infectious disease and pulmonology specialists.

How strong is the evidence?

Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free